Journals / Turkish Journal of Pharmaceutical Sciences / 2021 / Cilt: 18 - Sayı: 3

Hepatoprotective Activity of Gentisic Acid on 5-Fluorouracil-induced Hepatotoxicity in Wistar Rats

Wistar Sıçanlarında Gentisik Asidin 5-Florourasil Kaynaklı Hepatotoksisite Üzerindeki Hepatoprotektif Aktivitesi

Pages
92–97
Publication Date
2022-11-02
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: The results of the study highlighted the potential of GA as a hepatoprotective agent for the prevention of 5-FU-induced hepatotoxicity.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: 5-Fluorouracil (5-FU) is a very potent and effective antineoplastic drug that has been widely used for the management of various types of cancer.
📊
Key Findings & Data:However, the clinical use of 5-FU is often associated with severe toxicities including hepatotoxicity, which limit its therapeutic use as a potent anticancer agent.
💡
Conclusion & Impact:Conclusion: The results of the study highlighted the potential of GA as a hepatoprotective agent for the prevention of 5-FU-induced hepatotoxicity.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: 5-Fluorouracil (5-FU) is a very potent and effective antineoplastic drug that has been widely used for the management of various types of cancer. However, the clinical use of 5-FU is often associated with severe toxicities including hepatotoxicity, which limit its therapeutic use as a potent anticancer agent. The present study aimed to evaluate the hepatoprotective activity of a plant phenolic acid, gentisic acid (GA) (2,5-dihyroxybenzoic acid), against hepatotoxicity induced by 5-FU administration in Wistar rats. Materials and Methods: The rats were randomly divided into six groups, with six rats per group. Among these, group I and II served as normal control and 5-FU control groups, respectively. The rats in these groups received distilled water (1 mL/kg) for 14 days by oral route. Groups III, IV, V, and VI served as test groups and received GA at doses of 3, 10, 30, and 100 mg/kg body weight, respectively, via oral route for 14 days. From Day 9 onwards, all the groups, except group I, received intraperitoneal dose of 5-FU (20 mg/kg body weight) for five days up to day 14. At the end of the study, the rats were sacrificed, blood was withdrawn for biochemical estimations, and hepatic tissues were excised for histopathological evaluations. Results: Administration of 5-FU at a dose of 20 mg/kg body weight resulted in a significant increase in the serum levels of hepatic biomarkers, including aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, direct bilirubin, and total bilirubin. In comparison to these, 5-FU treatment resulted in a reduction in total protein content (TPC). This was accompanied by significant histopathological changes in the hepatic tissues of the rats, indicating severe hepatotoxicity. Pre- and co-administration of GA with 5-FU at doses of 30 and 100 mg/kg body weight for 14 days resulted in a dose-dependent amelioration of the 5-FU induced alterations in the biochemical and histopathological parameters. Conclusion: The results of the study highlighted the potential of GA as a hepatoprotective agent for the prevention of 5-FU-induced hepatotoxicity.

Özet

Amaç: 5-Florourasil (5-FU), çeşitli kanser türlerinin tedavisinde yaygın olarak kullanılan çok güçlü ve etkili bir antineoplastik ilaçtır. Bununla birlikte, 5-FU’nun klinik kullanımı genellikle, güçlü bir antikanser ajan olarak terapötik kullanımını sınırlayan hepatotoksisite dahil olmak üzere ciddi toksisitelerle ilişkilidir. Bu çalışmada, Wistar sıçanlarında 5-FU uygulaması ile uyarılan hepatotoksisiteye karşı bir bitki fenolik asiti olan gentisik asidin (GA) (2,5-dihiroksibenzoik asit) hepatoprotektif aktivitesini değerlendirmeyi amaçladık. Gereç ve Yöntemler: Sıçanlar rastgele olarak grup başına altı sıçan olacak şekilde altı gruba ayrıldı. Bunlar arasında grup I ve II, sırasıyla normal kontrol ve 5-FU kontrol grupları olarak belirlendi. Bu gruplardaki sıçanlar 14 gün boyunca oral yolla damıtılmış su (1 mL/kg) aldı. Gruplar III, IV, V ve VI test grupları olarak görev yaptı ve 14 gün boyunca oral yoldan sırasıyla 3, 10, 30 ve 100 mg/kg vücut ağırlığı dozlarında GA aldı. Dokuzuncu günden itibaren, grup I hariç tüm gruplar, 14. güne kadar beş gün boyunca 5-FU (20 mg/kg vücut ağırlığı) intraperitoneal doz aldı. Çalışmanın sonunda, biyokimyasal analiz için kanları alındıktan sonra sıçanlar sakrifiye edildi ve hepatik dokular histopatolojik değerlendirmeler için eksize edildi. Bulgular: 20 mg/kg vücut ağırlığı dozunda 5-FU uygulaması aspartat aminotransferaz, alanin aminotransferaz, alkalen fosfataz, bilirubin ve toplam bilirubin dahil olmak üzere hepatik biyobelirteçlerin serum seviyelerinde önemli bir artışa neden olmuştur. Bunlarla karşılaştırıldığında, 5-FU tedavisi toplam protein içeriğinde bir azalmaya yol açtı. Buna, sıçanların hepatik dokularında şiddetli hepatotoksisiteyi gösteren önemli histopatolojik değişiklikler eşlik etti. GA’nın 14 gün boyunca 30 ve 100 mg/kg vücut ağırlığı dozlarında 5-FU ile önceden ve birlikte uygulanması, biyokimyasal ve histopatolojik parametrelerde 5-FU kaynaklı değişikliklerde doza bağlı bir iyileşme ile sonuçlanmıştır. Sonuç: Çalışmanın sonuçları, GA’nın 5-FU ile indüklenen hepatotoksisitenin önlenmesi için bir hepatoprotektif ajan olarak potansiyelini vurguladı.

🔖

Cite This Article

PUJARI, R. R., BANDAWANE, D. D. (2022). Hepatoprotective Activity of Gentisic Acid on 5-Fluorouracil-induced Hepatotoxicity in Wistar Rats. Turkish Journal of Pharmaceutical Sciences, Cilt: 18 - Sayı: 3, 92–97. https://ajindex.com/articles/613642

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Perry MC. Chemotherapeutic agents and hepatotoxicity. Semin Oncol. 1992;19:551-565. Zimmerman HJ. Hepatotoxic effects of oncotherapeutic and immunosuppressive agents. In: Zimmerman HJ, ed. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver, (2nd ed). Philadelphia: Lippincott Williams & Wilkins: 1999;673-708.
  2. Caballero GA, Ausman RK, Quebbeman EJ. Long-term, ambulatory, continuous IV infusion of 5-FU for the treatment of advanced adenocarcinomas. Cancer Treat Rep. 1985;69:13-15.
  3. Ghoshal K, Jacob ST. An alternative molecular mechanism of action of 5-fluorouracil, a potent anticancer drug. Biochem Pharmacol. 1997;53:1569-1575.
  4. Backus HH, Pinedo HM, Wouters D, Kuiper CM, Jansen G, van Groeningen CJ, Peters GJ. Differences in the induction of DNA damage, cell cycle arrest and cell death by 5-fluorouracil and antifolates. Oncol Res. 2000;12:231-239.
  5. Moertel CG, Fleming TR, MacDonald JS, Haller DG, Laurie JA. Hepatic toxicity associated with fluorouracil, levamisole adjuvant therapy. J Clin Oncol. 1993;11:2386-2390.
  6. Tateishi T, Watanabe M, Nakura H, M Tanaka, T Kumai, S F Sakata, N Tamaki, Ogura K, Nishiyama T, Watabe T, Kobayashi S. Dihydropyrimidine dehydrogenase activity and fluorouracil pharmacokinetics with liver damage induced by bile duct ligation in rats. Drug Metab Dispos. 1999;27:651-654.
  7. Ray S, Roy K, Sengupta C. In vitro evaluation of protective effects of ascorbic acid and water extract of Spirulina plantesis (blue green algae) on 5-fluorouracil-induced lipid peroxidation. Acta Pol Pharm. 2007;64:335-344.
  8. Oettle H, Pelzer U, Hochmuth K, Diebold T, Langrehr J, Schmidt CA, Arning M, Vogl TJ, Neuhaus P, Huhn D, Riess H. Phase I trial of gemcitabine (Gemzar), 24 h infusion 5-fluorouracil and folinic acid in patients with inoperable pancreatic cancer. Anticancer Drugs. 1999;10:699-704.
  9. Li XP, Wen F, Yang W, Deng YB, Li M, Zhang PF, Tang RL, Li Q, Wei YQ. The role of tiopronin for the prevention of chemotherapy-related liver toxicity in advanced colorectal cancer patients treated with mFOLFOX7: a prospective analysis. Tumori. 2014;100:446-451.
  10. Khan R, Khan AQ, Qamar W, Lateef A, Tahir M, Rehman MU, Ali F, Sultana S. Chrysin protects against cisplatin-induced colon toxicity via amelioration of oxidative stress and apoptosis: probable role of p38 MAPK and p53. Toxicol Appl Pharmacol. 2012a;258:315-329.
  11. Khan R, Khan AQ, Qamar W, Lateef A, Tahir M, Rehman MU, Ali F, Sultana S. Chrysin abrogates cisplatin induced oxidative stress, p53